TherapeuticsMD, Inc. (TXMD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

TherapeuticsMD, Inc. (TXMD) is up 22.7% since the beginning of the year. At $2 per share, TXMD is trading 32.2% below its 52-week high of $3. Investors who bought $1,000 worth of TXMD shares 5 years ago would now be looking at an investment worth $33.

TherapeuticsMD, Inc. (TXMD) has returned 22.70% so far this year and 83.49% over the past 12 months. Over the last ten years, TXMD has returned -41.36% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Dec 11, 2003, TXMD's average daily return is +2.26%, while the average monthly return is +39.84%. At this rate, an investment would double in approximately 0.2 years.

Historically, 42% of months were positive and 58% were negative. The best month was Oct 2011 with a return of +9,900.0%, while the worst month was Aug 2009 at -86.7%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 9 months.

On a daily basis, TXMD closed higher 32% of trading days. The best single day was Oct 31, 2011 with a return of +9,900.0%, while the worst single day was Aug 24, 2009 at -86.7%.

TherapeuticsMD, Inc. has an annualized alpha of 35622.16%, beta of -2.45, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 11, 2003.

• This stock participated in 186.65% of S&P 500 Index downside but only 95.87% of its upside - more exposed to losses than it benefited from rallies.
• Beta of -2.45 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TXMD ranks 77 for risk / return — better than 77% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the TherapeuticsMD, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TherapeuticsMD, Inc. was 99.89%, occurring on Aug 24, 2011. Recovery took 546 trading sessions.

The current TherapeuticsMD, Inc. drawdown is 99.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of TherapeuticsMD, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how TherapeuticsMD, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.